NCT06663332

Who might be able to join this trial:

• You must have already completed all planned doses in the original pediatric guselkumab study.
• The study doctor must believe that you are still benefiting from continuing guselkumab treatment.
• If you are able to have children, you must either not be sexually active, be practicing abstinence, or be using a highly effective form of birth control — and agree to continue doing so during the study and for 12 weeks after the last dose.
• A parent or legal guardian must sign a consent form showing they understand the study and agree to allow their child to take part.
• Children who are old enough to understand the study (usually age 7 and older) must also agree to participate, and teenagers who agreed to join will be asked to sign an adult consent form when they reach adulthood.

Who may not be able to join:

• You are 18 or older and live in a country where this medication has been approved for adults for more than 2 years.
• You are under 18 and live in a country where this medication has been approved for children for more than 2 years.
• You are currently pregnant, breastfeeding, planning to become pregnant, or planning to father a child.
• You have used any treatments that are not allowed by the study before receiving your first dose in this extension study.
• You or a close family member work for the study doctor or study site and are directly involved in running this or related studies.
• The study doctor believes, for any reason, that joining the study would not be in your best interest or could interfere with how the study is carried out (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.